{
    "nctId": "NCT06504719",
    "briefTitle": "Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan",
    "officialTitle": "Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients With Advanced Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Metastatic Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 312,
    "primaryOutcomeMeasure": "The primary endpoint was toxicity rate of each drug",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed metastatic/recurrent breast cancer\n* 18 years of age\n* Triple-negative (TNBC), HER2-positive and/or hormone receptor positive advanced breast cancer\n* Treatment with an ADC at any of line of treatment\n* Treatment with at least one cycle of T-DXd and/or SG\n\nExclusion Criteria:\n\n* NA",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}